A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Trial Profile

A Phase II, Randomized, Open-Label, Three-Arm Study Comparing Low- and High-Dose Alemtuzumab and High-Dose Subcutaneous Interferon Beta-1a (Rebif) in Patients With Early, Active Relapsing-Remitting Multiple Sclerosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Oct 2017

At a glance

  • Drugs Alemtuzumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Genzyme Corporation; Sanofi
  • Most Recent Events

    • 28 Oct 2017 Results of analysis providing updated pregnancy outcomes in alemtuzumab-treated female patients from the clinical development program trials (NCT00050778, [NCT00530348, NCT00548405, NCT00930553, NCT02255656) presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 27 Jun 2017 Results of post hoc pooled analysis comparing efficacy of alemtuzumab and ocrelizumab based on number needed to treat (NNT) from CAMMS223,CARE-MS I, CARE-MS II and OPERA I and II studies,presented at the 3rd Congress of the European Academy of Neurology.
    • 28 Apr 2017 Results comparing efficacy of alemtuzumab and ocrelizumab based on number needed to treat (NNT) pooled analysis from CAMMS223,CARE-MS I, CARE-MS II and OPERA I and II studies, presented at the 69th Annual Meeting of the American Academy of Neurology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top